INIS
cancer
100%
patients
90%
lung cells
61%
plasma
35%
drugs
28%
doses
23%
metastases
23%
mutants
22%
humans
22%
pancreas
22%
concentration
19%
mutations
18%
molecules
16%
validation
16%
lungs
16%
hplc
16%
interactions
15%
temperature range 0273-0400 k
13%
anticoagulants
13%
kinases
13%
edta
12%
toxicity
11%
evaluation
11%
range
10%
tumors
10%
tyrosine
9%
clinical trials
9%
populations
8%
methanol
8%
comparative evaluations
7%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
54%
Osimertinib
33%
Pancreatic Cancer
22%
Small Molecule Inhibitors
20%
High Performance Liquid Chromatography-tandem Mass Spectrometry (HPLC-MS/MS)
16%
Phase I Study
16%
Drug Interactions
15%
Colorectal Cancer
13%
Direct Oral Anticoagulants
13%
KRAS mutant
12%
Patient Characteristics
11%
Human Plasma
11%
Encorafenib
11%
MS Method
11%
KRAS mutation
11%
Selumetinib
11%
Systematic Evaluation
11%
Afatinib
11%
Lung Cancer
11%
Alectinib
11%
Cetuximab
11%
EDTA Plasma
9%
Clinical Practice
8%
Room Temperature
8%
MEK Inhibitor (MEKi)
8%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
7%
Pan-HER Inhibitor
7%
Randomized Clinical Trial
6%
Plasma Trough Concentration
6%
Clinical Practice Research Datalink
6%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
58%
Osimertinib
27%
Pharmacokinetics
22%
Epidermal Growth Factor Receptor
22%
Pancreas Cancer
22%
Lung Cancer
22%
Drug-Drug Interaction
15%
Colorectal Carcinoma
14%
Direct Oral Anticoagulant
13%
Ethylenediaminetetraacetic Acid
12%
Malignant Neoplasm
11%
Encorafenib
11%
Selumetinib
11%
Cetuximab
11%
Brigatinib
11%
Lorlatinib
11%
Alectinib
11%
High Performance Liquid Chromatography
11%
Afatinib
11%
Clinical Trial
8%
Methanol
8%
Nivolumab
8%
Randomized Clinical Trial
8%
Neoplasm
8%
Protein Tyrosine Kinase Inhibitor
6%
Monoclonal Antibody
6%
Progression Free Survival
6%
Gefitinib
5%
Ammonium Formate
5%
Non-Steroidal Anti-Inflammatory Drug
5%
